A Phase 2 interventional study of VAY736 and Placebo in Relapse Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Terminated at 5 sites in 3 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Novartis.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 24th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2013, is one of 6 in phase 2, and was the 20th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →1 of the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis is open now, in 1 country. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada
Ages 18–99
By country, each count listing its studies:
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 147 across the 26 interventional studies, 251 across the 8 observational. Of the 28 that completed or were terminated, 19 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Multiple Sclerosis, Relapsing-Remitting by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05090371Novartis PharmaceuticalsA Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation | 2027-04-13 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a randomized, partially blinded, placebo-controlled, non-confirmatory study to assess the effects of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis (RRMS).
The study was planned to be conducted in approximately 96 patients. However, after enrolling 8 patients, the recruitment was terminated based on strategic considerations.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
This study's enrollment of 8 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Browse Multiple Sclerosis, Relapsing-Remitting studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Multiple Sclerosis, Relapsing-Remitting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Sclerosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key inclusion criteria:
A relapsing-remitting course of disease with:
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous infusion of VAY736
Drug: VAY736
Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16
Drug: Placebo
Single intravenous infusion of VAY736 (10 mg/kg)
Also known as: Lanalumab
Placebo to VAY736
Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 8, 12 and 16
The effect of VAY736, compared to placebo on the cumulative number of new gadolinium \[Gd\]-enhancing lesions on T1-weighted brain MRI scans in relapsing-remitting multiple sclerosis (RRMS) patient population at weeks 8, 12 and 16. Only descriptive statistics performed.
Time frame: Week 8, Week 12, Week 16
Number of All T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
Time frame: Week 4, Week 8, Week 12, Week 16
Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all new T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
Time frame: Week 4, Week 8, Week 12, Week 16
Number of New or Enlarging T2-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 hyperintense lesions (new or enlarging T2-weighted lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
Time frame: Week 4, Week 8, Week 12, Week 16
T2 Burden of Disease (Total Volume of T2-weighted Lesions) at Weeks 4, 8, 12 and 16.
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 burden of disease. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
Time frame: Week 4, Week 8, Week 12, Week 16
Number of Subjects Without Any New MRI Disease Activity at Weeks 4, 8, 12 and 16.
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess patients without any new MRI disease activity (no new Gd-enhancing lesions nor new or enlarging T2 lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
Time frame: Week 4, Week 8, Week 12, Week 16
Proportion of Relapse-free Patients Over the 16 Weeks of the Treatment Period.
A relapse is defined as the appearance of a new neurological abnormality, or worsening of previously stable, or improving pre-existing neurological abnormality, separated by at least 30 days from the onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\<37.5 C) or infection. A relapse was considered confirmed when confirmed by an Extended disability status scale (EDSS)-certified physician who was not involved in the treatment of the patient, was blinded to treatment allocation, and had no access to patient medical records. It was recommended that this occurs within 5 days of the onset of symptoms. A relapse was confirmed when it was accompanied by an increase of at least half a point (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Only descriptive statistics performed.
Time frame: Week 0 (Day 1), Week 4, Week 8, Week 12, Week 16
Number of Participants With On-Treatment Adverse Events, Serious Adverse Event, and Death
Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that VAY736 is safe for the treatment of patients with relapsing-remitting multiple sclerosis through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive statistics performed.
Time frame: From first dosing (single administration, Day 1) up to End of Study Visit (EOS) depending on B cell recovery (ranging from week 48 to 216)
This study was conducted in 5 centers in 3 countries: Czech Republic (1), Ukraine (2 sites) and USA (2 sites).
| Milestone | VAY736 | Placebo to VAY736 |
|---|---|---|
| Started | 4 | 4 |
| Pharmacodynamic (pd) analysis set | 4 | 4 |
| Completed | 3 | 4 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
The effect of VAY736, compared to placebo on the cumulative number of new gadolinium \[Gd\]-enhancing lesions on T1-weighted brain MRI scans in relapsing-remitting multiple sclerosis (RRMS) patient population at weeks 8, 12 and 16. Only descriptive statistics performed.
| Lesions | VAY736 | Placebo to VAY736 |
|---|---|---|
| Week 8 | 5 | 1 |
| Week12 | 5 | 2 |
| Week 16 | 6 | 3 |
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
| Lesions | VAY736 | Placebo to VAY736 |
|---|---|---|
| Week 4 | 19 | 2 |
| Week 8 | 20 | 2 |
| Week 12 | 20 | 3 |
| Week 16 | 21 | 4 |
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all new T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
| Lesions | VAY736 | Placebo to VAY736 |
|---|---|---|
| Week 4 | 4 | 1 |
| Week 8 | 1 | 0 |
| Week 12 | 0 | 1 |
| Week 16 | 1 | 1 |
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 hyperintense lesions (new or enlarging T2-weighted lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
| Lesions | VAY736 | Placebo to VAY736 |
|---|---|---|
| Week 4 | 279 | 94 |
| Week 8 | 277 | 93 |
| Week 12 | 276 | 91 |
| Week 16 | 264 | 91 |
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 burden of disease. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
| mm3 of T2-weighted lesions | VAY736 | Placebo to VAY736 |
|---|---|---|
| Week 4 | 20108.9 | 17706 |
| Week 8 | 18998.9 | 16785 |
| Week 12 | 18484.1 | 15996 |
| Week 16 | 18102.7 | 17919 |
Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess patients without any new MRI disease activity (no new Gd-enhancing lesions nor new or enlarging T2 lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.
| Participants | VAY736 | Placebo to VAY736 |
|---|---|---|
| Week 4 | 4 | 2 |
| Week 8 | 1 | 0 |
| Week 12 | 0 | 1 |
| Week 16 | 3 | 3 |
A relapse is defined as the appearance of a new neurological abnormality, or worsening of previously stable, or improving pre-existing neurological abnormality, separated by at least 30 days from the onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\<37.5 C) or infection. A relapse was considered confirmed when confirmed by an Extended disability status scale (EDSS)-certified physician who was not involved in the treatment of the patient, was blinded to treatment allocation, and had no access to patient medical records. It was recommended that this occurs within 5 days of the onset of symptoms. A relapse was confirmed when it was accompanied by an increase of at least half a point (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Only descriptive statistics performed.
| Participants | VAY736 | Placebo to VAY736 |
|---|---|---|
| Week 0 (Day 1) — Relapse-free | 4 | 4 |
| Week 0 (Day 1) — Relapse | 0 | 0 |
| Week 4 — Relapse-free | 4 | 4 |
| Week 4 — Relapse | 0 | 0 |
| Week 8 — Relapse-free | 4 | 4 |
| Week 8 — Relapse | 0 | 0 |
| Week 12 — Relapse-free | 4 | 4 |
| Week 12 — Relapse | 0 | 0 |
| Week 16 — Relapse-free | 3 | 3 |
| Week 16 — Relapse | 1 | 1 |
Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that VAY736 is safe for the treatment of patients with relapsing-remitting multiple sclerosis through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive statistics performed.
| Participants | VAY736 Administered at Visit 2 (Day 1) | VAY736 Administered at Visit 7 (Week 16 - Week 17) | Placebo Administered at Visit 2 |
|---|---|---|---|
| On-treatment Adverse Events (AEs) | 4 | 3 | 1 |
| On-treatment Serious Adverse Events (SAEs) | 0 | 0 | 0 |
| On-treatment Deaths | 0 | 0 | 0 |
Collected over Adverse events and serious adverse events were collected from first dosing (single administration, Day 1) up to End of Study Visit (EOS) depending on B cell recovery (ranging from week 48 to 216).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VAY736 Administered at Visit 2 (Day 1) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| VAY736 Administered at Visit 7 (Week 16 - Week 17) | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Placebo Administered at Visit 2 | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Event | VAY736 Administered at Visit 2 (Day 1) | VAY736 Administered at Visit 7 (Week 16 - Week 17) | Placebo Administered at Visit 2 |
|---|---|---|---|
| TachycardiaCardiac disorders | 3/4 | 0/4 | 0/4 |
| NauseaGastrointestinal disorders | 3/4 | 1/4 | 0/4 |
| HeadacheNervous system disorders | 3/4 | 1/4 | 1/4 |
| AstheniaGeneral disorders | 2/4 | 0/4 | 0/4 |
| ChillsGeneral disorders | 2/4 | 0/4 | 0/4 |
| LymphopeniaBlood and lymphatic system disorders | 0/4 | 1/4 | 0/4 |
| PalpitationsCardiac disorders | 1/4 | 0/4 | 0/4 |
| VomitingGastrointestinal disorders | 1/4 | 0/4 | 0/4 |
| HyperthermiaGeneral disorders | 1/4 | 0/4 | 0/4 |
| PyrexiaGeneral disorders | 1/4 | 1/4 | 0/4 |
| Age, Continuous(Years) | VAY736 | Placebo to VAY736 | Total |
|---|---|---|---|
| Mean | 32.0 ± 10.42 | 42.0 ± 2.45 | 37.0 ± 8.82 |
| Sex: Female, Male(Participants) | VAY736 | Placebo to VAY736 | Total |
|---|---|---|---|
| Female | 2 | 3 | 5 |
| Male | 2 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | VAY736 | Placebo to VAY736 | Total |
|---|---|---|---|
| Caucasian | 3 | 4 | 7 |
| Other | 1 | 0 | 1 |
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2013 to primary completion in May 2015, 16 months.
Results were first posted in Oct 2019, 4 years 5 months after primary completion. A results delay was requested in Oct 2018.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ianalumab
Multiple Sclerosis, Relapsing-Remitting →